BioWorld (Citeline) – Featured Feeds

Promatix EGFR×EphA2 Bispecific ADC Exerts Antitumor Activity

Today’s brief highlights four pre‑clinical advances: Paratus Sciences unveiled PS‑1001, a pan‑inflammasome blocker targeting IL‑1β and IL‑18 for hidradenitis suppurativa; researchers identified the SCAN circuit as a core pathway disrupted in Parkinson’s disease; RX‑10616 demonstrated enhanced radiotherapy response in head‑and‑neck...

United Unveils Newly Partnered Soft Mist Inhaler; Mannkind Sinks

United Therapeutics announced a partnership to launch a soft‑mist inhaler, targeting more efficient pulmonary drug delivery for its pipeline. The collaboration marks a strategic pivot away from traditional propellant‑based devices and positions United in the growing soft‑mist market. Investors reacted...

Money Raised by Biopharma

Recent biopharma research highlights IL‑22 and TL1A as a powerful biomarker pair for diagnosing hidradenitis suppurativa (HS), while TL1A overexpression is confirmed in patient lesions. Parallel studies reveal that inhibiting the NLRP3 inflammasome may mitigate vascular cognitive impairment and stroke‑related...

In the Clinic for Feb. 20, 2026

The February 20 2026 "In the Clinic" roundup aggregates a broad set of industry snapshots, special reports, and infographics covering biopharma, medical technology, and emerging research areas. It links to data on mRNA vaccine research, China’s GLP‑1 market, pulsed‑field ablation for atrial...

Investors Unfazed by Uncertainties Around Tariffs in Med Tech

Investors remain steady in the med‑tech sector despite lingering tariff uncertainties, signaling confidence in long‑term growth. At the same time, research updates highlight the SCAN circuit as a core driver of Parkinson’s disease, TL1A overexpression in hidradenitis suppurativa, and an...

LPM-5140276 Shows Enhanced Antitumor Efficacy in Combination with RMC-4550

Researchers reported that the novel KRAS G12D inhibitor LPM-5140276 markedly improves antitumor activity when paired with the SHP2 inhibitor RMC-4550. The combination demonstrated synergistic tumor regression in preclinical models of pancreatic and colorectal cancers harboring KRAS G12D mutations. Data suggest enhanced pathway...

Unnatural Products Signs $1.8B Cardio Pact with Novartis

Gilead-Genhouse's $1.5B+ Deal Boosts Synthetic Lethality Push

Gilead to Acquire Genhouse in $1.5B+ Deal to Accelerate Synthetic Lethality

Gilead Sciences announced a deal to acquire Genhouse for over $1.5 billion, aiming to strengthen its synthetic lethality oncology pipeline. The acquisition brings Genhouse’s portfolio of synthetic lethality drug candidates and technology into Gilead’s pipeline, underscoring its commitment to precision oncology.

Unnatural Products Secures $1.8B Cardio Pact with Novartis

Biotech firm Unnatural Products announced a $1.8 billion partnership with pharmaceutical giant Novartis to develop cardiovascular therapies. The agreement includes a corporate investment from Novartis, marking a significant funding boost for Unnatural Products.

Biopharma Money Raised: Jan. 1-Feb. 12, 2026

BioWorld’s latest brief highlights three emerging biotech advances. Researchers pinpointed the SCAN network as a central circuit disrupted in Parkinson’s disease, offering a new therapeutic target. Astellas presented promising preclinical data on ASP-2246, an mRNA‑encoded NeuroD1 candidate aimed at neural...

Quantx Secures $85M Funding to Accelerate Oral Immunology Pipeline

Quantx, a biotech firm focused on oral immunology, announced a $85 million financing round to advance its drug candidates. The new capital will fund preclinical and early clinical development, expanding its pipeline in the immunology space.